Recherche

Publications

1. Determinants and effects of positive surgical margins after prostatectomy on prostate cancer mortality: a population-based study. Retèl VP, Bouchardy C, Usel M, Neyroud-Caspar I, Schmidlin F, Wirth G, Iselin C, Miralbell R, Rapiti E. BMC Urol. 2014 Nov 5;14(1):86. doi: 10.1186/1471-2490-14-86. IF: 13.61

2. Optimization of Radiation Therapy Techniques for Prostate Cancer With Prostate-Rectum Spacers: A Systematic Review. Mok G, Benz E, Vallee JP, Miralbell R, Zilli T. Int J Radiat Oncol Biol Phys. 2014 Oct 1;90(2):278-288. doi: 10.1016/j.ijrobp.2014.06.044. Review. IF: 4.176

3. Results of Dose-adapted Salvage Radiotherapy After Radical Prostatectomy Based on an Endorectal MRI Target Definition Model. Zilli T, Jorcano S, Peguret N, Caparrotti F, Hidalgo A, Khan HG, Vees H, Miralbell R. Am J Clin Oncol. 2014 Sep 18. [Epub ahead of print]. IF: 2.611

4. Editorial Comment from Dr Zilli and Dr Miralbell to Early radiotherapy after radical prostatectomy improves cancer-specific survival only in patients with highly aggressive prostate cancer: Validation of recently released criteria. Zilli T, Miralbell R. Int J Urol. 2014 Sep 4. doi: 10.1111/iju.12614. [Epub ahead of print] No abstract available. IF: 1.91 

5. 11C-Choline PET/CT in the primary diagnosis of prostate cancer: impact on treatment planning. Garcia JR, Jorcano S, Soler M, Linero D, Moragas M,  Riera E, Miralbell R, Lomeña F. Q J Nucl Med Mol Imaging. 2014 May 21. [Epub ahead of print]. IF: 1.724 

6. In vivo quality assurance of volumetric modulated arc therapy for ano-rectal cancer with thermoluminescent dosimetry and image-guidance. Dipasquale G, Nouet P, Rouzaud M, Dubouloz A, Miralbell R, Zilli T. Radiother Oncol. 2014 Jun;111(3):406-11. doi: 10.1016/j.radonc.2014.04.014. Epub 2014 May 15. IF: 4.67 

7. PET/CT imaging and the oligometastatic prostate cancer patient: an opportunity for a curative approach with high-dose radiotherapy? Miralbell R, Buchegger F. Eur J Nucl Med Mol Imaging. 2014 Jul;41(7):1267-9. doi: 10.1007/ s00259-014-2793-8. No abstract available. IF: 5.217 

8. Absorbable hydrogel spacer use in men undergoing prostate cancer radiotherapy: 12 month toxicity and proctoscopy results of a prospective multicenter phase II trial. Uhl M, Herfarth K, Eble MJ, Pinkawa M, van Triest B, Kalisvaart R, Weber DC, Miralbell R, Song DY, DeWeese TL. Radiat Oncol. 2014 Apr 24;9:96. doi: 10.1186/1748-717X-9-96. IF: 2.36

9. Prostate-rectum spacers: optimization of prostate cancer irradiation. Zilli T, Benz E, Miralbell R. Cancer Radiother. 2014 Jun;18(3):215-21; quiz 243-4, 247. doi: 10.1016/j.canrad.2014.03.001. Epub 2014 Apr 18. Review. French. IF: 4.67 

10. Pelvic Lymph Node Irradiation Including Pararectal Sentinel Nodes for Prostate Cancer Patients: Treatment Optimization Comparing Intensity Modulated X-rays, Volumetric Modulated Arc Therapy, and Intensity Modulated Proton Therapy. Vees H, Dipasquale G, Nouet P, Zilli T, Cozzi L, Miralbell R. Technol Cancer Res Treat. 2014 Apr 1. IF: 1.886 

11. Hypofractionated external beam radiotherapy to boost the prostate with >85 Gy/equivalent dose for patients with localised disease at high risk of lymph node involvement: feasibility, tolerance and outcome. Zilli T, Jorcano S, Escudé L, Linero D, Rouzaud M, Dubouloz A, Miralbell R. Clin Oncol (R Coll Radiol). 2014 Jun;26(6):316-22. doi:10.1016/jclon.2014.02.014. Epub 2014 Mar 22. IF: 2.826

12. A modelled comparison of prostate cancer control rates after high-dose-rate brachytherapy (3145 multicentre patients) combined with, or in contrast to, external-beam radiotherapy. Roberts SA, Miralbell R, Zubizarreta EH, Fowler JF, Hendry JH. Radiother Oncol. 2014 Apr;111(1):114-9. doi: 0.1016/j.radonc.2014.01.008. Epub 2014 Feb 20. IF: 4.67 

13. Planning for the future: cancer incidence projections in Switzerland up to 2019. Rapiti E, Guarnori S, Pastoors B, Miralbell R, Usel M. BMC Public Health. 2014 Feb 1;14:102. doi: 10.1186/1471-2458-14-102. IF: 2.321 

14. First imaging results of an intraindividual comparison of (11)C-acetate and (18)F-fluorocholine PET/CT in patients with prostate cancer at early biochemical first or second relapse after prostatectomy or radiotherapy. Buchegger F, Garibotto V, Zilli T, Allainmat L, Jorcano S, Vees H, Rager O, Steiner C, Zaidi H, Seimbille Y, Ratib O, Miralbell R. Eur J Nucl Med Mol Imaging. 2014 Jan;41(1):68-78. doi: 10.1007/s00259-013-2540-6. Epub 2013 Oct 9. IF 5.217

15. Dose-adapted salvage radiotherapy after radical prostatectomy based on an erMRI target definition model: toxicity analysis. Zilli T, Jorcano S, Peguret N, Caparrotti F, Hidalgo A, Khan HG, Vees H, Weber DC, Miralbell R. Acta Oncol. 2014 Jan;53(1):96-102. IF: 3.71

16. Interaction of w-3 polyunsaturated fatty acids with radiation therapy in tyo different colorectal cancer cell lines. Cai F, Sorg O, Granci V, Lecumberri E, Miralbell R, Dupertuis YM, Pichard C. Clin Nutr. 2014 Feb;33(1):164-70. doi: 10.1016/j.clnu.2013.04.005. Epub 2013 Apr 23. IF: 3.94

17. Whole-breast irradiation with or without a boost for patients treated with breast-conserving surgery for early breast cancer: 20-year follow-up of a randomized phase 3 trial. Bartelink H, Maingon Ph, Poortmans Ph, Weltens C, Fourquet A, Jager J., Schinagl D, Oei B, Rodenhuis C, Horiot J.-C, Struikmans H., Van Limbergen E, Kirova Y, Elkhuizen P, Bongartz R, Miralbell R, Morgan D,Dubois J.-B, Remouchamps V, Mirimanoff R.-O, Collette S, Collette L. On behalf of the European Organisation for Research and Treatment of Cancer radiation Oncology and Breast Cancer Groups Lancet Oncol 2014 Published online December 9.2014 http//dx.doi.org/10.1016/S1470-2045(14)71156-8. IF: 24.229

18. The Quadrella: a novel approach to analyzing optimal outcomes after permanent seed prostate brachytherapy. Tétreault-Laflamme A, Zilli T, Meissner A, Larrivée S, Sylvestre MP, Delouya G, Taussky D. Radiother Oncol. 2014 Apr;111(1):110-3. doi: 10.1016/j.radonc.2014.01.017. Epub 2014 Feb 20. IF: 4.67 

19. History of the rare cancer network and past research. Mirimanoff RO, Ozsahin M, Thariat J, Ozyar E, Schick U, Pehlivan B, Krengli M, Pellanda AF, Vees H, Cai L, Scandolaro L, Belkacemi Y, Villà S, Igdem S, Lutsyk M, Miller RC. Rare Tumors. 2014 Aug 6;6(3):5462. doi: 10.4081/rt.2014.5462. eCollection 2014 Jul 30.

20. First year experience with IORT for breast cancer at the Geneva University Hospitals. Vinh-Hung V, Nepote V, Rozenholc A, Vees H, Monnier S, Castiglione-Gertsch M, Fargier-Bochaton O, Popowski Y, Rouzaud M, Petignat P, Nouet P, Dubouloz A, Miralbell R Translational Cancer Research 2014 (in press).

21. The effect of surgical titanium rods on proton therapy delivered for cervical bone tumors: experimental validation using an anthropomorphic phantom. Dietlicher I, Casiraghi M, Ares C, Bolsi A, Weber DC, Lomax AJ, Albertini F. Phys Med Biol. 2014 Dec 7;59(23):7181-94. doi: 10.1088/0031-9155/59/23/7181. Epub 2014 Nov 4. IF:2.922 

22. Tumor control and QoL outcomes of very young children with atypical teratoid/rhabdoid Tumor treated with focal only chemo-radiation therapy using pencil beam scanning proton therapy. Weber DC, Ares C, Malyapa R, Albertini F, Calaminus G, Kliebsch U, Mikroutsikos L, Morach P, Bolsi A, Lomax T, Schneider R. J Neuro oncol. 2014 Nov 2. IF: 2.787 

23. Choline-PET in prostate cancer management: the point of view of the radiation oncologist. De Bari B, Alongi F, Lestrade L, Giammarile F. Crit Rev Oncol Hematol. 2014 Sep;91(3):234-47. doi: 10.1016/j.critrevonc.2014.04.002. Epub 2014 Apr 28. IF: 4.0646 

24. External beam radiotherapy ± chemotherapy in the treatment of anal canal cancer: a single-institute long-term experience on 100 patients. De Bari B, Buglione M, Maddalo M, Lestrade L, Spiazzi L, Vitali P, Barbera F, Magrini SM. Cancer Invest. 2014 Jul;32(6):248-55. doi: 10.3109/07357907.2014.907420. Epub 2014 Apr 25. IF: 2.06 

25. Role of brachytherapy in the treatment of cancers of the anal canal. Long-term follow-up and multivariate analysis of a large monocentric retrospective series. Lestrade L, De Bari B, Pommier P, Montbarbon X, Lavergne E, Ardiet JM, Carrie C. Strahlenther Onkol. 2014  Jun;190(6):546-54. doi: 10.1007/s00066-014-0628-y. Epub 2014 Mar 11. IF: 2.733 

26. Meningiomas: knowledge base, treatment outcomes, and uncertainties. A RANO review. Rogers L, Barani I, Chamberlain M, Kaley TJ, McDermott M, Raizer J, Schiff D, Weber DC, Wen PY, Vogelbaum MA. J Neurosurg. 2014 Oct 24:1-20. [Epub ahead of print]. IF: 3.227

27. Long-term outcome of patients with spinal myxopapillary ependymoma: treatment results from the MD Anderson Cancer Center and institutions from the Rare Cancer Network. Weber DC, Wang Y, Miller R, Villà S, Zaucha R, Pica A, Poortmans P, Anacak Y, Ozygit G, Baumert B, Haller G, Preusser M, Li J. Neuro Oncol. 2014 Oct 9. pii: nou293. [Epub ahead of print]. IF: 2.787

28. Quality assurance standards drive improvements in the profile of radiation therapy departments participating in trials of the EORTC Radiation Oncology Group. Grant W, Hurkmans CW, Poortmans PM, Maingon P, Monti AF, van Os MJ, Weber DC. Radiother Oncol. 2014 Sep 30. pii: S0167-8140(14)00390-9. doi: 10.1016/j.radonc.2014.09.003. [Epub ahead of print]

29. Atypical meningoma: current management dilemmas and prospective clinical trials. Jenkinson MD, Weber DC, Haylock BJ, Mallucci CL, Zakaria R, Javadpour M. J Neuro oncol. 2014 Sep 26. [Epub ahead of print]. IF: 2.787 

30. Novel radiotherapy techniques for involved-field and involved-node treatment of mediastinal Hodgkin lymphoma: when should they be considered and which questions remain open? Lohr F, Georg D, Cozzi L, Eich HT, Weber DC, Koeck J, Knäusl B, Dieckmann K, Abo-Madyan Y, Fiandra C, Mueller RP, Engert A, Ricardi U. Strahlenther Onkol. 2014 Oct;190(10):864-6, 868-71. doi: 10.1007/s00066-014-0719-9. Epub 2014 Sep 11. IF: 2.733

31. Radiotherapy versus Observation following surgical resection of Atypical Meningioma (the ROAM trial). Jenkinson MD, Weber DC, Haylock BJ, Mallucci CL, Zakaria R, Javadpour M. Neuro Oncol. 2014 Nov;16(11):1560-1. doi: 10.1093/ neuonc/nou149. Epub 2014 Jul 19. No abstract available. IF: 5.287

32. IMRT credentialing for prospective trials using institutional virtual phantoms: results of a joint European Organization for the Research and Treatment of Cancer and Radiological Physics Center project. Weber DC, Vallet V, Molineu A, Melidis C, Teglas V, Naudy S, Moeckli R, Followill DS, Hurkmans CW. Radiat Oncol. 2014 May 29;9:123. doi: 10.1186/1748-717X-9-123. IF: 2.36 

33. Outcome impact and cost-effectiveness of quality assurance for radiotherapy planned for the EORTC 22071-24071 prospective study for head and neck cancer. Weber DC, Hurkmans CW, Melidis C, Budach W, Langendijk JH, Peters LJ, Grégoire V, Maingon P, Combescure C. Radiother Oncol. 2014 Jun;111(3):393-9. doi: 10.1016/j. radonc.2014.04.015. Epub 2014 May 23. IF: 4.67 

34. Radiation therapy quality assurance in clinical trials--Global Harmonisation Group. Melidis C, Bosch WR, Izewska J, Fidarova E, Zubizarreta E, Ishikura S, Followill D, Galvin J, Xiao Y, Ebert MA, Kron T, Clark CH, Miles EA, Aird EG, Weber DC, Ulin K, Verellen D, Hurkmans CW. Radiother Oncol. 2014 Jun;111(3):327-9. doi: 10.1016/j. radonc.2014.03.023. Epub 2014 May 8. No abstract available. IF: 4.67

35. Phase I study of sorafenib combined with radiation therapy and temozolomide as first-line treatment of highgrade glioma. Hottinger AF, Aissa AB, Espeli V, Squiban D, Dunkel N, Vargas MI, Hundsberger T, Mach N, Schaller K,Weber DC, Bodmer A, Dietrich PY. Br J Cancer. 2014 May 27;110(11):2655-61. doi: 10.1038/bjc.2014.209. Epub 2014 May 1. IF: 4.817

36. Absorbable hydrogel spacer use in men undergoing prostate cancer radiotherapy: 12 month toxicity and proctoscopy results of a prospective multicenter phase II trial. Uhl M, Herfarth K, Eble MJ, Pinkawa M, van Triest B, Kalisvaart R, Weber DC, Miralbell R, Song DY, DeWeese TL. Radiat Oncol. 2014 Apr 24;9:96. doi: 10.1186/1748- 717X-9-96. IF: 2.36 37. SEER analysis and statistical judgment. Smoll NR, Weber DC. J Neurosurg. 2014 Feb;120(2):578-9. doi: 10.3171/2012.11.JNS121921. Epub 2013 Nov 29. No abstract available. IF: 3.227